See the DrugPatentWatch profile for vyndaqel
What is “Vyndaqel” and who holds the patent?
Vyndaqel is the brand name for tafamidis, a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). Patent rights for tafamidis are held by the company that developed the drug and its related inventions, and they are enforced through a mix of compound, formulation, method-of-use, and jurisdiction-specific patents.
When does the Vyndaqel (tafamidis) patent expire?
Patent expiration depends on the specific patent family and the country (the same drug can have different expiration dates across the US, EU/UK, and other jurisdictions). You typically need the exact jurisdiction and, ideally, the patent/application numbers to state a date accurately.
Is Vyndaqel protected by “patent plus exclusivity” (not just patents)?
Yes. Even after the last patent in a given jurisdiction expires, drug regulators often provide additional market exclusivity periods (for example, data/market exclusivity rules tied to approvals). Those can delay entry of generic or follow-on versions even when some patents expire.
Can a generic or biosimilar/“follow-on” tafamidis enter before patents expire?
In practice, follow-on products for small-molecule drugs like tafamidis generally can’t be marketed until patents and exclusivity protections in that jurisdiction are cleared. Developers sometimes seek approvals earlier via the regulatory pathway while litigation determines whether they can launch.
How to find the exact patent expiry date for tafamidis in your country
To get the correct “when does it expire” answer, you need:
- the country (US vs EU vs UK vs another)
- whether you mean “first generic/follow-on launch allowed” or “last patent expiration”
- the exact product (Vyndaqel vs Vyndamax can have different protection terms)
- the relevant patent family numbers
If you share your country, I can narrow it down
Tell me the jurisdiction you mean (for example, United States or European Union/UK) and whether you’re asking about Vyndaqel (tafamidis meglumine) or another tafamidis brand/product, and I’ll structure the answer around the specific patent and exclusivity timeline for that location.
Sources: none provided.